Daiichi Sankyo Aims for Cancer Drug Growth
Archived Content: This article was published over 30 days ago. Travel rules and prices may have changed.Check official sources.
Daiichi Sankyo plans to double oncology revenue by 2030. The Japanese drugmaker aims to be a top 5 global oncology player by 2035.
While seemingly unrelated to travel, advancements in healthcare can indirectly impact your experience in Japan. A strong pharmaceutical sector contributes to the overall health and well-being of the population, potentially affecting the availability of medical services and supplies for tourists.
Daiichi Sankyo's focus on oncology drug development signifies a commitment to innovation and healthcare advancement within Japan. This investment could lead to improved medical infrastructure and access to cutting-edge treatments.
For travelers, this means potentially greater peace of mind knowing that Japan continues to invest in its healthcare system. While you hopefully won't need it, a robust healthcare sector is always a reassuring factor when traveling abroad.
Original source:The Japan Times ↗
More Japan News
As Zimbabwe’s raw lithium ban pays off, ambitions grow
Buoyed by the development, the small southern African country is determined to go much further in its drive for local processing of its resources.
How are you supposed to wash a Japanese futon duvet at the laundromat?
Sure, that big, fluffy down blanket is a must for making it through a Japanese winter, but how are you supposed to clean it when summer comes around? Generally, living in Japan means hanging your laun
Studio Ghibli adds new Ponyo glassware to its anime lineup for summer
Stay cool with a little help from a Ghibli seaside town. When temperatures rise in Japan, so too does our desire for some cool respite, preferably along the lines of a seaside adventure like the one i